204 related articles for article (PubMed ID: 25981902)
21. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
22. Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer.
Bohn BA; Mina S; Krohn A; Simon R; Kluth M; Harasimowicz S; Quaas A; Bockhorn M; Izbicki JR; Sauter G; Marx A; Stahl PR
Hum Pathol; 2013 Aug; 44(8):1524-33. PubMed ID: 23465274
[TBL] [Abstract][Full Text] [Related]
23. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
24. Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.
Kluth M; Runte F; Barow P; Omari J; Abdelaziz ZM; Paustian L; Steurer S; Christina Tsourlakis M; Fisch M; Graefen M; Tennstedt P; Huland H; Michl U; Minner S; Sauter G; Simon R; Adam M; Schlomm T
Int J Cancer; 2015 Nov; 137(10):2354-63. PubMed ID: 26009879
[TBL] [Abstract][Full Text] [Related]
25. YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein.
Shen X; Zhong J; Yu P; Zhao Q; Huang T
Biochem Biophys Res Commun; 2019 Feb; 509(2):448-454. PubMed ID: 30594392
[TBL] [Abstract][Full Text] [Related]
26. [PTEN gene in triple-negative breast cancer].
Karseladze AI; Kulevich EE; Karseladze DA; Poddubnaia IV
Arkh Patol; 2010; 72(5):20-3. PubMed ID: 21313761
[TBL] [Abstract][Full Text] [Related]
27. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
[TBL] [Abstract][Full Text] [Related]
28. Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer.
Schäfer SA; Hülsewig C; Barth P; von Wahlde MK; Tio J; Kolberg HC; Bernemann C; Blohmer JU; Kiesel L; Kolberg-Liedtke C
Future Oncol; 2019 Jun; 15(16):1921-1938. PubMed ID: 31140870
[No Abstract] [Full Text] [Related]
29. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer.
Depowski PL; Rosenthal SI; Ross JS
Mod Pathol; 2001 Jul; 14(7):672-6. PubMed ID: 11454999
[TBL] [Abstract][Full Text] [Related]
30. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.
Dean SJ; Perks CM; Holly JM; Bhoo-Pathy N; Looi LM; Mohammed NA; Mun KS; Teo SH; Koobotse MO; Yip CH; Rhodes A
Am J Clin Pathol; 2014 Mar; 141(3):323-33. PubMed ID: 24515759
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh.
Noman AS; Uddin M; Rahman MZ; Nayeem MJ; Alam SS; Khatun Z; Wahiduzzaman M; Sultana A; Rahman ML; Ali MY; Barua D; Ahmed I; Islam MS; Aboussekhra A; Yeger H; Farhat WA; Islam SS
Sci Rep; 2016 Jan; 6():18830. PubMed ID: 26727947
[TBL] [Abstract][Full Text] [Related]
32. AKAP3 correlates with triple negative status and disease free survival in breast cancer.
Esmaeili R; Majidzadeh-A K; Farahmand L; Ghasemi M; Salehi M; Khoshdel AR
BMC Cancer; 2015 Oct; 15():681. PubMed ID: 26458542
[TBL] [Abstract][Full Text] [Related]
33. Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.
Jézéquel P; Loussouarn D; Guérin-Charbonnel C; Campion L; Vanier A; Gouraud W; Lasla H; Guette C; Valo I; Verrièle V; Campone M
Breast Cancer Res; 2015 Mar; 17():43. PubMed ID: 25887482
[TBL] [Abstract][Full Text] [Related]
34. MGMT and PTEN as potential prognostic markers in breast cancer.
Neto JC; Ikoma MM; Carvalho KC; Vassallo J; De Brot M; Gobbi H; Soares FA; Rocha RM
Exp Mol Pathol; 2012 Feb; 92(1):20-6. PubMed ID: 22019339
[TBL] [Abstract][Full Text] [Related]
35. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
36. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA
Breast J; 2015; 21(6):627-33. PubMed ID: 26547900
[TBL] [Abstract][Full Text] [Related]
37. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
38. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
39. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Tang JM; He QY; Guo RX; Chang XJ
Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
[TBL] [Abstract][Full Text] [Related]
40. CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid.
Liu RZ; Garcia E; Glubrecht DD; Poon HY; Mackey JR; Godbout R
Mol Cancer; 2015 Jul; 14():129. PubMed ID: 26142905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
